ChroMedX Submits US Provisional Patent Application for Recently Developed Aspects of HemoPalm Blood Analysis System
March 10, 2015
ChroMedX Corp. (the “Company”) (CSE: CHX, OTC: MNLIF, Frankfurt: EIY2), a developer of in vitro diagnostics and point-of-care testing (POCT) technologies is pleased to announce the filing of a second US Provisional Patent Application pertaining to the HemoPalm Cartridge and Analyzer system.
The second US Provisional Patent Application No. 62/114,700 entitled “Joint Spectroscopic and Biosensor System for Point-of-Care Testing” was filed on 11th Feb 2015, and describes recently developed aspects of the Company’s HemoPalm Cartridge and Analyzer system. The first US Provisional Patent Application No. 62/006,066 was filed on 31st May 2014. In May 2015, an international patent application (PCT) will be filed, claiming priority to the two US Provisional Patent Applications. This PCT has the potential to effectively extend the lifespan of our issued US Patent pertaining to HemoPalm, and to provide patent protection outside the US, in particular Europe, China and India.
“We continue our efforts in expanding the Company’s Intellectual Property portfolio and are very pleased with the progress made to date”, said Dr. Wayne Maddever , ChroMedX Corp., President & CEO
The Company’s HemoPalm and Ultrafiltration technologies are covered by several issued and pending patents. A list of issued and pending patents can be found on the company's website here: http://www.chromedx.com/intellectual-property/
About ChroMedX Corp.
ChroMedX Corp. is a medical technology company focused on the development of novel medical devices for in vitro diagnostics and point-of-care testing. The devices are protected by the Company’s issued and pending patents, pertaining to blood collection, analysis and plasma/serum processing.
Follow ChroMedX Corp.:
W. Clark Kent
NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATIONS SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.